Antheia

Antheia is a next-generation pharmaceutical ingredient manufacturer founded in 2015 by Dr. Christina Smolke and Dr. Kristy Hawkins, based on research from the Smolke Lab at Stanford University. The company uses advanced synthetic biology to engineer yeast that efficiently reconstructs complex biosynthetic pathways, converting simple sugars into pharmaceutical key starting materials (KSMs) and active pharmaceutical ingredients (APIs) through fermentation. Antheia's platform addresses critical global drug shortages by replacing fragile agricultural and chemical synthesis supply chains with scalable, domestic biomanufacturing, with a mission to ensure essential medicines are accessible to the over two billion people worldwide who currently lack reliable access.